Are Peptides Safe? What the Research Evidence Shows

For GLP-1-class peptides such as semaglutide, the most common documented adverse reactions — each reported in at least 5% of patients in the trials behind its FDA label — are gastrointestinal: nausea, diarrhoea, vomiting, constipation, abdominal pain, and related effects such as dyspepsia and abdominal distension. In clinical trials, 6.8% of semaglutide-treated patients discontinued treatment because of an adverse reaction, versus 3.2% on placebo, mostly for nausea, vomiting, or diarrhoea.^[1]

For growth-hormone-releasing peptides such as tesamorelin, the dominant pattern is different: its FDA label documents injection-site reactions (erythema, pruritus, pain, bruising) in 25% of treated patients versus 14% on placebo during the first 26 weeks, alongside hypersensitivity reactions and edema-related effects such as arthralgia and carpal tunnel syndrome. Our tesamorelin guide covers that evidence in full.^[5]

For a handful of approved peptide drugs, yes. Semaglutide's pivotal STEP 1 trial followed 1,961 adults for 68 weeks of treatment, and a follow-up extension tracked a subset for a further year off treatment. Semaglutide's FLOW trial followed 3,533 adults with type 2 diabetes and chronic kidney disease for a median of 3.4 years — the kind of multi-year, randomised, controlled follow-up that produces genuine long-term safety and efficacy data.^[2][4]

For most compounds sold as 'research peptides,' that evidence does not exist yet. A 2025 narrative review of BPC-157 found only three published human pilot studies — covering knee pain, interstitial cystitis, and intravenous safety and pharmacokinetics — and concluded that the absence of high-quality human trials limits any real assessment of its human safety. Preclinical data and a single pilot study can be reassuring, but they are not the same evidence base as a multi-year randomised trial.^[6]

The best available long-term organ-outcome data for any peptide points the other way from 'harm': in the FLOW trial, patients with type 2 diabetes and chronic kidney disease who received semaglutide had a 24% lower risk of major kidney-disease events — a composite of kidney failure, a 50% drop in kidney function, or kidney- or cardiovascular-related death — than those on placebo, over a median 3.4 years of follow-up (hazard ratio 0.76).^[4]

That result is specific to semaglutide, to that patient population, and to kidney outcomes — it does not mean 'peptides' as a class protect or harm the liver or kidneys. Liver-fat effects have been reported for at least one other peptide in a specific clinical population; see our tesamorelin guide for that data. For most other research peptides, no published human liver- or kidney-safety data exists at all.

Semaglutide's FDA label carries a boxed warning: in rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumours at clinically relevant exposures. Whether it causes thyroid C-cell tumours, including medullary thyroid carcinoma, in humans is unknown — the human relevance of the rodent finding has not been established — and the drug is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.^[1]

Growth-hormone-releasing peptides such as tesamorelin raise a different, mechanism-specific caution: because they stimulate a known growth factor, their FDA label requires any pre-existing malignancy to be inactive and fully treated before starting, and treatment is stopped if a malignancy recurs. That is a monitoring and contraindication requirement built around a specific mechanism in a specific drug class — it is not published evidence that peptides in general cause cancer.^[5]

There is no substantial published evidence that peptides, as a category, cause hair loss. The mechanism most strongly linked to pattern hair loss is androgenic: dihydrotestosterone acting on androgen receptors in genetically susceptible hair follicles, a pathway associated with androgens such as anabolic-androgenic steroids rather than with most studied peptides. A 2018 review notes androgenic alopecia affects roughly 80% of men and 50% of women over a lifetime and that the androgen/DHT link is the accepted consensus, even though the exact step-by-step mechanism is still debated.^[8]

One small trial points the other way for at least one peptide complex: in 45 men with male-pattern hair loss, a copper-free complex of the tripeptide GHK with 5-aminolevulinic acid increased hair count over 6 months (by 52.6 to 71.5 hairs per cm² across two doses, versus 9.6 for placebo) with no reported adverse events. It was a single small trial with no effect on hair thickness or length, not confirmation that any specific product regrows hair.^[7]

The best-documented example is semaglutide. In the STEP 1 trial extension, participants who had lost an average 17.3% of body weight by week 68 regained 11.6 percentage points of that loss within a year of stopping treatment, against 1.9 points for those who had been on placebo — leaving a net loss of 5.6% at week 120 versus 0.1% for placebo. Most of the cardiometabolic improvements measured during treatment reverted toward baseline over that same year off treatment.^[3][2]

That pattern — benefit fading after stopping — is specific to how semaglutide works and was only measured because researchers kept following people after they stopped treatment. For compounds without completed human research, there is no published data either way on what happens after stopping. Confirming the compound itself is genuine is a separate question from this one; read our quality protocol for that.